Rate represents the percentage of commission on sale of any shares of common stock sold.

No definition available.

Name:	tgtx_CommissionRate
Namespace Prefix:	tgtx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount represents the maximum value of securities to be sold by company.

+ References

No definition available.

+ Details

Name:	tgtx_MaximumSecuritiesToBeSold
Namespace Prefix:	tgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount represents the maximum aggregate offering price of additional shares to be issued.

+ References

No definition available.

+ Details

Name:	tgtx_OfferingPriceAdditionalSharesToBeIssued
Namespace Prefix:	tgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the value eligible to receive regulatory filing, approval and sales based milestones during the period.

+ References

No definition available.

+ Details

Name:	tgtx_SaleBasedMileStonePayment
Namespace Prefix:	tgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Cash received on stock transaction after deduction of issuance costs.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockConsiderationReceivedOnTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockConsiderationReceivedPerTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockPricePerShare
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_SubsequentEventLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

SUBSEQUENT EVENTS (Details Textual) (USD $)	12 Months Ended		1 Months Ended
SUBSEQUENT EVENTS (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2015
Subsequent Event [Line Items]
Sale of Stock, Price Per Share	$ 10.31us-gaap_SaleOfStockPricePerShare
Research and Development Expense, Total	$ 40,086,347us-gaap_ResearchAndDevelopmentExpense	$ 13,662,680us-gaap_ResearchAndDevelopmentExpense
Subsequent Event [Member] \| MLV & Co. LLC [Member]
Subsequent Event [Line Items]
Maximum Securities To Be Sold	250,000,000
Offering Price Additional Shares to Be Issued	75,000,000
Commission Rate	3.00%
Subsequent Event [Member] \| Checkpoint Therapeutics Collaboration Agreement [Member] \| Up-front Payment Arrangement [Member]
Subsequent Event [Line Items]
Research and Development Expense, Total			500,000
Subsequent Event [Member] \| Checkpoint Therapeutics Collaboration Agreement [Member] \| Development And Sales Based Milestone Payments [Member]
Subsequent Event [Line Items]
Sale Based Mile Stone Payment			164,000,000
Subsequent Event [Member] \| 2015 At-the-Market Issuance Sales Agreement [Member]
Subsequent Event [Line Items]
Sale of Stock, Price Per Share	$ 14.36
Sale of Stock, Number of Shares Issued in Transaction	1,369,777
Sale of Stock, Consideration Received Per Transaction	19,700,000
Sale of Stock, Consideration Received on Transaction	$ 19,300,000